Clinical Trial Update: ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

View source ↗

Summary

Guardant Health's ORACLE trial is currently recruiting to evaluate residual cancer using a liquid biopsy across multiple cancer types.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Cutaneous Melanoma
• Esophageal Cancer
• Gastric Cancer
• Invasive Breast Cancer
• Non-small Cell Lung Cancer
• Renal Pelvis Cancer
• Ureteral Cancer

Snippet

Sponsor: Guardant Health, Inc. | Conditions: Bladder Carcinoma, Ureter Carcinoma | Status: RECRUITING